Sun Pharmaceutical agrees to pay $200 million to end payers in US generic drug suit
MLex Summary: Sun Pharmaceutical has agreed to pay $200 million to settle US antitrust claims from end purchasers accusing it of fixing the prices of generic pharmaceuticals, according to a statement...To view the full article, register now.
Already a subscriber? Click here to view full article